Genmab

	18/4 11:18 af StockBull	These sorts of numbers are larger than would be required by clinical trials, so suggest that Gilead is ramping up production for clinical use. The firm also said it was hoping to increase output again as raw materials became available. Looking further ahead, at even broader use, the firm has set an “ambitious goal” of producing more than 500,000 treatment courses by October, and 1m by the end of the year, from a geographically diverse group of suppliers.
	18/4 11:17 af StockBull	Even if the drug proves successful, it is still experimental, and only limited quantities of such drugs are usually available. Gilead has increased production to meet demand for use in trials. On April 5th, it said it had enough to supply more than 140,000 patients.
	18/4 11:16 af StockBull	any conclusions was "premature and scientifically unsound".
	18/4 11:15 af StockBull	For all the excitement it generated, the STAT report was little more than a leaked conversation between doctors. It revolved around a trial at the University of Chicago with 125 patients, mostly severely ill with covid-19. One of the doctors is reported as saying that most of the patients had been discharged and only two had died. But even if this is correct, the lack of a placebo group makes it hard to assess the real worth of the drug. The University of Chicago itself warned that drawing any
	18/4 11:13 af StockBull	However the study has proven divisive among scientists. To begin with, errors can be large given the small number of patients. Moreover, the trial was not “randomised”, so there is no way of knowing whether the sample properly reflects the population of severely afflicted patients. Last, there was no comparison group that was given a placebo, ie, a substance with no therapeutic effect, to establish the real effectiveness of the drug.
	18/4 11:13 af StockBull	Remdesivir: science remains equivocal about whether this drug actually works for covid-19 sufferers. Two trials in China have already failed, because of lack of enrolment. (China started its trials relatively late in its epidemic, so it was hard to recruit sufficient numbers of patients.) The recent publication in the New England Journal of Medicine, of a study of remdesivir given to 53 severely afflicted patients, reported that 68% of them improved.
	18/4 09:10 af Solsen	Korrekt GB (link)
	18/4 08:06 af bibob	God morgen. :-)
	18/4 07:59 af Helge Larsen/PI-redaktør	God morgen. :-)
	17/4 22:15 af Bulder	Stærkt us-luk. Ikke mindst trukket op af remdesivir-rygterne. Så må vi se om de holder.
	17/4 21:23 af GeorgeBest	I 2015 var vi vist højere på NBI...
	17/4 20:56 af Solsen	Vi mangler lidt over 3% for at NBI er i ATH :-)
	17/4 20:21 af Solsen	Well we dont know about ADC-301. You could be right...
	17/4 20:07 af E L	haha, fortunately there are enough here to correct all my mistakes ;-)
	17/4 20:05 af Solsen	Thanks EL you are a master :-)
	17/4 19:55 af E L	New BMS-986253 trial: Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19 (link)
	17/4 19:00 af E L	yes, that is certainly also possible,... i was actually happy that they finished so quick and just in time before corona shut recruitment down, but maybe exactly that happened... :(
	17/4 17:23 af gentogen	EL 15.47: I am not so sure. That would be extremely quick. They are including new location in new countries in the trial so perhaps it is just for the time being they are not recruiting?
	17/4 17:21 af Solsen	Tilfredshed herfra og god weekend :-)
	17/4 17:20 af JKY_VH	Den er absolut godkendt og god weekend:-)
	17/4 17:15 af gdn55	Kan ugen godkendes? Jeg er meget tilfreds, frygtede det værste.
	17/4 15:47 af E L	ADCT-301 Ph II seems fully accrued (link)
	17/4 14:03 af Plimsoller	Good. We need smart people to help these days.
	17/4 13:59 af E L	Van de Winkel adds: ‘Our scientists will also use their knowledge to help with the response to coronavirus disease, to add our expertise and our insights to create an effective therapeutic candidate much more rapidly (link)

	17/4 13:59 af E L	In response to the coronavirus crisis, the company has mandated its employees to work for hospitals, nursing homes and other institutions in the public healthcare if needed, and Genmab will continue to pay their salaries.
	17/4 12:41 af peter12	@E.L. Im refeering to a patient story I believe sounds trustworthy
	17/4 12:39 af E L	;-)
	17/4 12:28 af Sukkeralf	If Janssen say they are going to file it does not matter to me if it is based on phase 1/2 data or phase 2 data :-)
	17/4 12:27 af Sukkeralf	in cancer trials you normaly calls it phase 1/2 because you always treat patients right away. Genmab got daratumumab approved in third line Dara/POM/Dex based on phase 1/2 data
	17/4 12:20 af E L	@peter i am not sure, it is a bit confusing as clinical trials still mentions Ph I , and it was only last September that they added lazertinib to the trial
	17/4 11:56 af E L	(link)
	17/4 11:55 af E L	(link) Nature: Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting full art https://sci-hub.tw/(link)
	17/4 11:54 af E L	haha, any hint to Remdesivir in there? ;-)
	17/4 11:52 af nohope	I love your attitude ;-) Just the right attitude whenever you are doing in new medicne, if the preliminair news are good - then just stop investigating.
	17/4 11:46 af E L	@nohope thks- but i like the headline so much, don't need to read more :-)
	17/4 11:44 af fillipa	tusind tak god dag
	17/4 11:42 af fillipa	Tænker det stort set er samme certicat
	17/4 11:41 af fillipa	Ok tak og det er ikke der er til udløb har du evt en ISINkode til den .....
	17/4 11:39 af nohope	EL - you can get 14 days access for free at Dagens Medicin.(Unless you have already done that recently)
	17/4 11:32 af fillipa	Ved nogen hvorfor der ikke kan handles Gen 2N certificat hos Nordea får svar om at den ikke udbydes mere....
	17/4 11:29 af E L	i can only read the headline , but maybe it is of use for any of you (link)
	17/4 10:33 af troldmanden	Og hvad skulle det så være?
	17/4 10:21 af Legolas23	Jeg er overbevist om, vi får en fantastisk god nyhed i løbet af weekenden...
	17/4 09:56 af Helge Larsen/PI-redaktør	Skåret kop med hank set på pølsemandens disk ved siden af chilli-mayoen: (link)
	17/4 09:25 af JKY_VH	:-D
	17/4 09:11 af Mcjean	You forgot ........Esbjerg Havns pølsemands Investment Management LLC have increase it shares by 15% and own now more than before. Esbjergs Pølsemandsdaughters Invest Management LLC have increase there shares with 2 and therefore have a buyrating on the stock say the "Journal Vi Unge".
	17/4 08:55 af GeorgeBest	Assetmark Inc. now owns 5,301 shares of the company's stock valued at $118,000 after acquiring an additional 1,180 shares during the period. Institutional investors and hedge funds own 3.64% of the company's stock.
	17/4 08:55 af GeorgeBest	Kayne Anderson Rudnick Investment Management LLC increased its stake in Genmab A/S by 0.9% in the fourth quarter. Kayne Anderson Rudnick Investment Management LLC now owns 127,189 shares of the company's stock valued at $2,840,000 after purchasing an additional 1,170 shares during the last quarter. Finally, Assetmark Inc. boosted its holdings in shares of Genmab A/S by 28.6% in the fourth quarter.
	17/4 08:54 af GeorgeBest	PNC Financial Services Group Inc. now owns 10,932 shares of the company's stock worth $245,000 after purchasing an additional 810 shares in the last quarter. Comerica Bank increased its stake in Genmab A/S by 2.5% in the fourth quarter. Comerica Bank now owns 38,449 shares of the company's stock valued at $893,000 after purchasing an additional 944 shares during the last quarter.
	17/4 08:53 af GeorgeBest	A number of hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Group AG boosted its holdings in shares of Genmab A/S by 11.5% in the 4th quarter. UBS Group AG now owns 5,190 shares of the company's stock valued at $116,000 after acquiring an additional 537 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Genmab A/S by 8.0% during the fourth quarter.